Newsletter Tool

Today’s Big News

Oct 14, 2024

Lundbeck signs $2.5B check for Longboard, seeing blockbuster potential in epilepsy med

Lilly picks UK for first European Gateway Lab as part of $364M investment plan

Novartis channels Gargamel, terminating midphase SMURF1 trial

GSK's depemokimab reduces polyps in phase 3 trials, adding weight to upcoming filing

Transgene's viral cancer vaccine flunks midphase test—but subgroup signal spurs ongoing analysis

Jasper dials up dose after complete responses come and go quickly in hives trial

Featured

Lundbeck signs $2.5B check for Longboard, seeing blockbuster potential in epilepsy med

By James Waldron

After spying blockbuster potential in Longboard Pharmaceuticals’ epilepsy med, brain disease-focused pharma Lundbeck is scooping up the biotech for $2.5 billion.

Lilly picks UK for first European Gateway Lab as part of $364M investment plan

By James Waldron

Eli Lilly’s Gateway Labs is going global, with the U.K. government announcing today that the nation will host the first European branch of the innovation accelerator.

Novartis channels Gargamel, terminating midphase SMURF1 trial

By Nick Paul Taylor

Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis but will continue to advance the candidate in another indication.

Revolutionizing gene therapy logistics with Cryoport's Elite solution

GSK's depemokimab reduces polyps in phase 3 trials, adding weight to upcoming filing

By James Waldron

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials.

The sudden progress in rare kidney disease is built on years of dedication

Transgene's viral cancer vaccine flunks midphase test—but subgroup signal spurs ongoing analysis

By Nick Paul Taylor

Transgene’s therapeutic vaccine candidate TG4001 has flunked a phase 2 solid tumor trial. But, while the prospect failed to improve progression-free survival, the biotech is continuing to analyze aspects of the data including a “positive efficacy trend” in a prespecified subgroup before deciding on its next steps.

Jasper dials up dose after complete responses come and go quickly in hives trial

By Nick Paul Taylor

Jasper Therapeutics has reported complete responses in 10 of the 12 chronic hives patients who received the high dose of its c-Kit antibody. But with some patients relapsing within weeks, the biotech has begun trialing a higher dose in pursuit of deeper, more durable responses.

Pfizer doubles down with its 2nd FDA hemophilia approval in 6 months

By Kevin Dunleavy

For the second time in six months, the FDA approved a Pfizer treatment for hemophilia. On Friday the U.S. regulator signed off on Hympavzi, an anti-tissue factor pathway inhibitor for patients age 12 and older with hemophilia A or B.

Evonik telegraphs another 260 layoffs amid multiyear reorganization

By Fraiser Kansteiner

After Evonik in March unveiled a restructuring project that will result in up to 2,000 layoffs, the company is now announcing another round of job cuts as it retools portions of its drug ingredients and nutrition businesses.

‘I’m another statistic. I feel let down’: How HIV prevention stays out of reach for many

By Anastassia Gliadkovskaya,Sam Donndelinger

Ending the HIV epidemic hinges on both treatment and prevention, particularly through access to PrEP. For at-risk individuals living in the U.S. South—where HIV is a daunting reality—PrEP use is very low compared to the number of new HIV cases.

Fierce podcasts

Don’t miss an episode

A revival in neuro therapeutics

This week on "The Top Line," Fierce Pharma's Fraiser Kansteiner chats with industry leaders about the surge in neuroscience investment, breakthroughs and future targets in neuropharmaceuticals.

How do we prevent chronic kidney disease upstream?

Breaking down BIOSECURE—Industry implications and what comes next

Resources

eBook

Decoding the data

Need the superpowers to select the right lab equipment?

Sponsored by: PHC Corporation of North America

Whitepaper

Strategies to Optimize Expression Challenges of Multi-chain and Bispecific Antibodies

Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects.

Communicating the Value of Biopharma Assets to Potential Investors

How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights.

Presented by: Blue Matter

Whitepaper

Accelerating Timelines to Clinic with GPEx® Lightning

Unlock the Future of Biotherapeutics with Catalent Biologics!

Epilepsy Clinical Trials

Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner.